Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

SK bioscience Co.,Ltd. (302440) Price & Analysis

302440 Stock Chart & Stats

$32,750.00$550.00(1.71%)
At close: 4:00 PM EDT
$32,500$35,000$37,5003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$31,850.00 - $33,250.00
52-Week Range
$31,500.00 - $61,300.00
Previous Close
$32,200.00
Volume
N/A
Average Volume (3M)
60.82K
Market Cap
KRW 2.57T
Enterprise Value
KRW 2.76T
Total Cash (Recent Filing)
KRW 832.60B
Total Debt (Recent Filing)
KRW 543.37B
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Nov 05, 2026
EPS Estimate
-387.97
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Integrated Vaccine Capabilities

An integrated presence across vaccine R&D, clinical development, manufacturing and distribution gives the company control across the product lifecycle. Its mix of routine, preventive and pandemic-response vaccines can support multiple demand channels and preserve strategic relevance beyond one product.

Strong Equity Base

The sizable equity base provides a meaningful buffer against operating volatility and supports continued investment in vaccine development and production. This capital cushion can improve resilience over the next several quarters, even while profitability and cash generation remain under pressure.

Moderate Leverage

Moderate leverage reduces the balance-sheet burden relative to a heavily indebted biotechnology business and preserves more financial flexibility. Although returns are currently weak, the existing capital structure offers greater capacity to withstand losses and fund strategic priorities than high leverage would.

Bears Say

Severe Revenue Contraction

The extreme TTM revenue contraction indicates that recent commercial performance has weakened materially rather than merely fluctuating around a stable base. Sustained losses following earlier profitability raise execution risk and make it harder to support development spending, fixed costs and durable earnings recovery.

Deeply Negative Free Cash Flow

Deeply negative free cash flow shows that investment and other outflows are not currently supported by operating inflows. Persistent cash burn can increase funding needs, restrict strategic flexibility and make the business more vulnerable if weak revenue and profitability continue over the coming quarters.

Weak Returns And Rising Leverage

Although leverage remains moderate, its increase alongside negative returns on equity signals that the capital structure is not presently producing adequate profits. If operating performance stays weak, higher leverage may add financial pressure without generating the returns needed to rebuild earnings power.

SK bioscience Co.,Ltd. News

302440 FAQ

What was SK bioscience Co.,Ltd.’s price range in the past 12 months?
SK bioscience Co.,Ltd. lowest stock price was $31500.00 and its highest was $61300.00 in the past 12 months.
What is SK bioscience Co.,Ltd.’s market cap?
SK bioscience Co.,Ltd.’s market cap is ₩2.57T.
When is SK bioscience Co.,Ltd.’s upcoming earnings report date?
SK bioscience Co.,Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were SK bioscience Co.,Ltd.’s earnings last quarter?
SK bioscience Co.,Ltd. released its earnings results on Aug 10, 2026. The company reported -$179.59 earnings per share for the quarter, beating the consensus estimate of -$340.68 by $161.09.
Is SK bioscience Co.,Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does SK bioscience Co.,Ltd. pay dividends?
SK bioscience Co.,Ltd. does not currently pay dividends.
What is SK bioscience Co.,Ltd.’s EPS estimate?
SK bioscience Co.,Ltd.’s EPS estimate is -387.97.
How many shares outstanding does SK bioscience Co.,Ltd. have?
SK bioscience Co.,Ltd. has 78,456,550 shares outstanding.
What happened to SK bioscience Co.,Ltd.’s price movement after its last earnings report?
SK bioscience Co.,Ltd. reported an EPS of -$179.59 in its last earnings report, beating expectations of -$340.68. Following the earnings report the stock price went up 1.085%.
Which hedge fund is a major shareholder of SK bioscience Co.,Ltd.?
Currently, no hedge funds are holding shares in KR:302440
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology